We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2025 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Serum Marker-Editing Strategy to Improve Diagnosis of Neurological Diseases

By LabMedica International staff writers
Posted on 10 Dec 2025

Tracking gene-expression changes in the brain is crucial for understanding neurological diseases, yet current monitoring tools are invasive or unable to capture subtle activity shifts over time. One emerging alternative is the use of engineered serum markers—small proteins released by targeted brain cells into the bloodstream, where they can be measured with a simple blood test. These released markers of activity can sensitively track brain activity, but their long persistence in blood often obscures rapid or intervening biological changes. Now, researchers have developed a modified approach that clears older signals so new ones can be detected, enabling diagnosis of neurological diseases through a blood test.

Researchers at Rice University (Houston, Texas, USA) have developed a next-generation serum marker system designed to be erasable inside the bloodstream. In this technique, RMAs are engineered to be cleaved by a specific enzyme once they have served their purpose. When the enzyme is introduced, it cuts the marker apart, allowing the previous biological signal to disappear and enabling researchers to record new activity. This concept transforms the use of serum markers by allowing their behavior to be dynamically controlled in the body, rather than extracted and interpreted in a fixed state.


Image: Shirin Nouraein is the first author on the study that led to the new serum marker-editing strategy (Photo courtesy of Jorge Vidal/Rice University)
Image: Shirin Nouraein is the first author on the study that led to the new serum marker-editing strategy (Photo courtesy of Jorge Vidal/Rice University)

In an animal model, a single injection of the cleaving enzyme eliminated about 90% of the RMA background signal within 30 minutes, making it possible to detect subtle gene-expression changes that had previously gone unnoticed. The team also showed that markers could be repeatedly cleared and remeasured, offering a more detailed picture of how gene activity evolves over time. This level of temporal precision opens the door to monitoring how patients respond to therapy or how neurological conditions progress using minimally invasive blood tests.

The research, presented in Proceedings of the National Academy of Sciences, highlights how modifying serum markers inside the body could expand their diagnostic value far beyond neurology. By tuning how long markers last in circulation or resetting them when needed, clinicians may eventually detect a wide range of diseases more sensitively, including cancers or lung conditions, potentially through simple tests such as urine analysis. Future work aims to adapt the approach to additional biological pathways and evaluate its performance in broader preclinical models.

“The key advance here is a new way of thinking about serum markers ⎯ that we can modify them inside the bloodstream when we need to,” said assistant professor Jerzy Szablowski, corresponding author on the study. “This broad concept has many potential applications, ranging from extending the marker’s half-life to improve detectability, or erasing them to remove the background signal and improve temporal resolution."

Related Links:
Rice University


Gold Member
Automated MALDI-TOF MS System
EXS 3000
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Pipette
Accumax Smart Series
Silver Member
PCR Plates
Diamond Shell PCR Plates

Latest Molecular Diagnostics News

World’s First Genetic Type 1 Diabetes Risk Test Enables Early Detection
09 Dec 2025  |   Molecular Diagnostics

Blood Test to Help Low-Risk Gastric Cancer Patients Avoid Unnecessary Surgery
09 Dec 2025  |   Molecular Diagnostics

First-Of-Its-Kind Automated System Speeds Myeloma Diagnosis
09 Dec 2025  |   Molecular Diagnostics



GLOBE SCIENTIFIC, LLC